Fresh analysis indicates that individuals who come off blockbuster GLP-1 drugs like semaglutide or tirzepatide can put back on reduced body mass at a significantly accelerated pace than those who stop traditional diet and exercise plans.
Findings released in a leading medical journal points out that while overweight individuals frequently drop about a fifth of their total mass while on the medication, the mass is regained at an estimated rate of nearly a kilo each month once they quit.
"People using such medications must be informed of the risk of quick weight regain when the medication is stopped," stated lead investigator Dr. Susan Jebb.
This pace of recovery means a return to original mass in about one and a half years.
Comparing Treatments
The analysis, which looked at 37 of trials involving over 9,000 of participants, contrasted the effects of the injectable medications with older methods.
The team point out that individuals who lose weight through dieting generally see a slower creep back—approximately 0.1 kg a month—after stopping.
Understanding the Fast Regain
Nutrition scientists propose the mechanism of the injections accounts for the amplified weight return.
The injections mimic a body's own chemical called glucagon-like peptide-1, which helps regulate appetite.
"Sustained high doses of the hormone levels far above than normal may cause the system to produce less of its own natural GLP-1, and may also reduce sensitivity to its effects," explained Dr. Adam Collins, a nutrition specialist.
"Discontinuation of this GLP-1 'fix' results in hunger is no longer kept in check, making overeating a significant risk."
A Lifelong Disease?
Medical guidelines recommend the jabs for people with obesity-related medical conditions, alongside prescribed lifestyle changes.
Many experts contend that, given the high risk of weight regain, the therapy might need to be life-long.
This view is echoed by pharmaceutical companies, who say that the results "underscore the long-term nature of excess weight," akin to managing diseases like hypertension.
User Testimonies
People who have stopped the medication report a intense resurgence of appetite.
"I experienced something flipping and I was suddenly starving," recalled one woman.
This challenge is exacerbated if users have not developed sustainable dietary or behavioural changes during treatment.
Growing Use
Survey data suggest that millions of adults in the UK have used these injections in the last 12 months, with demand remaining high.
- Use is greater among women than men.
- The middle-aged demographic shows the highest usage rates.
- Many obtain the drugs through private healthcare rather than public health services.
Ultimately, clinicians emphasize that while GLP-1 drugs are effective tools for shedding pounds, they are not a magic cure and lasting health benefits relies on ongoing behavioural changes.
